Salk Institute scientists discovered that bile acids in the liver can weaken immune cell function, making immunotherapy less effective against liver cancer. They pinpointed specific bile acids that suppress T cells and found that supplementing with UDCA reversed the effect, controlling tumor growth in mice. Since UDCA is already used for liver disease, it could quickly translate into clinical trials.
